Factors | HBsAg-positive patients (n = 127) | HBsAg-negative patients (n = 293) | P value | ||
---|---|---|---|---|---|
No | % | No | % | ||
Age > 60 | 22 | 17.3 | 97 | 33.1 | 0.001* |
Gender | Â | Â | Â | Â | 0.116* |
 Male | 79 | 62.2 | 158 | 53.9 |  |
 Female | 48 | 37.8 | 135 | 46.1 |  |
Bulky mass (≥ 7.5 cm) | 22 | 17.3 | 52 | 17.7 | 0.916* |
Special sites involvement | Â | Â | Â | Â | Â |
 Liver | 6 | 4.7 | 10 | 3.4 | 0.519* |
 Spleen | 28 | 22.0 | 19 | 6.5 |  < .001* |
 Stomach | 11 | 8.6 | 34 | 11.6 | 0.371* |
 Intestinal | 3 | 2.3 | 33 | 11.2 | 0.003* |
 Waldeyer’ string | 26 | 20.5 | 71 | 24.2 | 0.401* |
 Bone | 9 | 7.1 | 12 | 4.1 | 0.196* |
Performance status | Â | Â | Â | Â | 0.425* |
 0–1 | 115 | 90.6 | 272 | 92.8 |  |
 2–4 | 12 | 9.4 | 21 | 7.2 |  |
B symptoms present | 28 | 22.0 | 76 | 26.0 | 0.396* |
Elevated LDH | 59 | 46.5 | 135 | 46.1 | 0.943* |
Ann Arbor stage | Â | Â | Â | Â | 0.028* |
 I–II | 55 | 43.3 | 161 | 54.9 |  |
 III–IV | 72 | 56.7 | 132 | 45.1 |  |
Extra-nodal sites ≥ 2 | 22 | 17.3 | 49 | 16.7 | 0.880* |
IPI score | Â | Â | Â | Â | 0.653* |
 0–1 | 103 | 81.1 | 232 | 79.2 |  |
 3–5 | 24 | 18.9 | 61 | 20.8 |  |
Use of rituximab | 60 | 47.2 | 143 | 48.8 | 0.769* |
Response to chemotherapy |  |  |  |  | 0.300†|
 Complete response | 78 | 61.4 | 196 | 66.9 |  |
 Partial response | 40 | 31.5 | 83 | 28.3 |  |
 Stable disease | 1 | 0.8 | 4 | 1.4 |  |
 Progressive disease | 7 | 5.5 | 10 | 3.4 |  |
 Not available | 1 | 0.8 | 0 | 0.0 |  |